Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

Stock factor profile

GUFIC BIO SC

GUFICBIO · Healthcare · Pharmaceuticals & Biotechnology

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra and currently employs 1,382 full-time employees. The company went IPO on 2004-10-19. The firm operates through the Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

Last price₹443.05
1 day+0.84%
1 month+11.59%
Model ratingLocked
Data as of04 Sep 2026

Performance

Price history

Equity review factors

Factor profile

Factor scores are part of the Wright portfolio review.

Run your free portfolio review

Fundamental snapshot

Fundamentals at a glance

Market cap3948
P/E ratio58.1
Factor betaLocked
VolatilityLocked
Model scoreLocked
Screen passLocked

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.